BioRestorative Therapies up as FDA clears change to study on cell therapy

Biorestorative Therapies

16/04/2024 14:21

** Shares of BioRestorative Therapies  BRTX.O  rise 15.2% to
$1.52 premarket
    ** Co says the U.S. FDA has cleared an amendment to the
protocol of its ongoing mid-stage study on cell therapy
candidate BRTX-100 for chronic lumbar disc disease (cLDD)
    ** Protocol amendment replaces saline injection in the
placebo group with a sham injection - BRTX
    ** Co says the amendment removes the possibility of
transient clinical outcomes in the placebo group
    ** "This positive change in our protocol will not have any
impact from a timing perspective, affirming our already
established 2024 enrollment completion target” - BRTX
    ** Up to last close, stock down 24% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))